The group's principal activities are to develop innovative therapeutics to treat serious and life-threatening diseases such as cancer, heart disease and diseases of the eye. The group is also developing cell transplantation technology for the treatment of human diseases which are characterized by cell dysfunction or cell death. The products of the group are tnferade, biobypass and adpedf. On 21-Aug-2003, the group acquired diacrin inc.
